ANNOUNCEMENT

Advisory Board Member Receives Lifetime Achievement Award

- Actinogen’s Clinical Advisory Board member, Professor Jeffrey Cummings, of the Cleveland Clinic, awarded prestigious Lifetime Achievement Award by the American Alzheimer’s Association at its international conference
- Award honours and recognises Professor Cummings significant contribution to global Alzheimer’s research
- Professor Cummings brings substantial academic and clinical research expertise to the Actinogen’s Clinical Advisory Board
- Reflects the exceptional calibre of internationally recognised academic experts supporting Actinogen’s development of Xanamem

Sydney 8 August 2018. Actinogen Medical ASX: ACW (‘ACW’ or ‘the Company’) is delighted to announce that one of its Clinical Advisory Board members, Professor Jeffrey Cummings M.D. Sc.D., was awarded a Lifetime Achievement Award from the American Alzheimer’s Association, at the recent Alzheimer’s Association International Conference (AAIC) 2018, in Chicago. The award is presented to honour individuals who have made a significant scientific contribution and lifetime commitment to progress the fight against Alzheimer’s disease and dementia.

Professor Cummings is a founding member of Actinogen’s Clinical Advisory Board and continues to provide invaluable advice and research expertise to the Company in the development for Xanamem.

The AAIC is the world’s largest conference for researchers focused on investigating and developing treatments for Alzheimer’s. The AAIC Lifetime Achievement Awards recognise the efforts and contributions of researchers who have furthered the understanding of Alzheimer’s disease.

Professor Cummings brings a wealth of knowledge and expertise to the field of brain health and clinical research, having founded the Cleveland Clinic Lou Ruvo Centre for Brain Health in Las Vegas, Nevada and Cleveland, Ohio. He is currently the Principal Investigator and Director of the NIH/NIGMS-funded Centre for Neurodegeneration and Translational Neuroscience, and the founding director of the UCLA Alzheimer’s Disease Research Centre.

CEO of Actinogen Medical, Dr Bill Ketelbey commented: “Having one of our Advisory Board members receive such a prestigious award reflects the exceptional calibre of internationally recognised academic experts supporting Actinogen’s development of Xanamem. Jeff is a renowned Alzheimer’s researcher and has devoted much of his life to researching and developing treatments to fight against this devastating disease. No one deserves this award more than Jeff and we’re delighted to have his intellect and research expertise to advise on the development of Xanamem”

ENDS

Actinogen Medical
Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
@BillKetelbey

Media Enquiries
Imogen Conyers
Media & Capital Partners
M: +61 405 191 257
E: imogen.conyers@mcppartners.com.au
About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer’s disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer’s disease is estimated to be US$250bn, and is set to increase to US$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer’s disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia.

About Xanamem™

Xanamem’s novel mechanism of action sets it apart from other Alzheimer’s treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the \(11\beta\text{-HSD1}\) enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer’s disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer’s disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer’s disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.